CY1122692T1 - Ενωσεις τετραϋδροπυραζολοπυριμιδινης - Google Patents

Ενωσεις τετραϋδροπυραζολοπυριμιδινης

Info

Publication number
CY1122692T1
CY1122692T1 CY20181101275T CY181101275T CY1122692T1 CY 1122692 T1 CY1122692 T1 CY 1122692T1 CY 20181101275 T CY20181101275 T CY 20181101275T CY 181101275 T CY181101275 T CY 181101275T CY 1122692 T1 CY1122692 T1 CY 1122692T1
Authority
CY
Cyprus
Prior art keywords
tetrahydropyrazolopyrimidine
compounds
tetrahydropyrazolopyrimidine compounds
sle
toll
Prior art date
Application number
CY20181101275T
Other languages
English (en)
Inventor
Roch Boivin
Eric Carlson
Atsushi Endo
Hans Hansen
Sally Ishizaka
Matthew MACKEY
Sridhar NARAYAN
Takashi Satoh
Shawn Schiller
Lynn D. Hawkins
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1122692T1 publication Critical patent/CY1122692T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Υλοποιήσεις της αποκάλυψης αφορούν ενώσεις τετραϋδροπυραζολοπυριμιδίνης που δρουν ως ανταγωνιστές ή αναστολείς για υποδοχείς τύπου-Toll 7 και/ή 8 και τη χρήση τους σε φαρμακευτικές συνθέσεις αποτελεσματικές για την αγωγή του συστηματικού ερυθηματώδους λύκου (SLE) και της νεφρίτιδας λύκου.
CY20181101275T 2012-05-31 2018-11-29 Ενωσεις τετραϋδροπυραζολοπυριμιδινης CY1122692T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261654023P 2012-05-31 2012-05-31
PCT/US2013/043679 WO2013181579A2 (en) 2012-05-31 2013-05-31 Tetrahydropyrazolopyrimidine compounds

Publications (1)

Publication Number Publication Date
CY1122692T1 true CY1122692T1 (el) 2020-07-31

Family

ID=48626649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101275T CY1122692T1 (el) 2012-05-31 2018-11-29 Ενωσεις τετραϋδροπυραζολοπυριμιδινης

Country Status (34)

Country Link
US (5) US9126999B2 (el)
EP (1) EP2855476B1 (el)
JP (2) JP6285918B2 (el)
KR (2) KR102403007B1 (el)
CN (2) CN104507939B (el)
AR (1) AR091236A1 (el)
AU (2) AU2013267204B8 (el)
BR (1) BR112014030060B1 (el)
CA (1) CA2874445C (el)
CL (1) CL2014003278A1 (el)
CY (1) CY1122692T1 (el)
DK (1) DK2855476T3 (el)
ES (1) ES2709119T3 (el)
HK (1) HK1203498A1 (el)
HR (1) HRP20181889T1 (el)
HU (1) HUE040562T2 (el)
IL (2) IL268013B2 (el)
JO (1) JO3407B1 (el)
LT (1) LT2855476T (el)
MX (1) MX368455B (el)
MY (1) MY172926A (el)
NZ (1) NZ703459A (el)
PE (2) PE20150220A1 (el)
PH (2) PH12014502660A1 (el)
PL (1) PL2855476T3 (el)
PT (1) PT2855476T (el)
RS (1) RS57977B1 (el)
RU (2) RU2677291C2 (el)
SG (1) SG11201407890VA (el)
SI (1) SI2855476T1 (el)
TW (1) TWI572606B (el)
UA (1) UA113440C2 (el)
WO (1) WO2013181579A2 (el)
ZA (1) ZA201409273B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
BR112016008378B1 (pt) 2013-10-14 2022-11-08 Eisai R&D Management Co., Ltd Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos
WO2015057659A1 (en) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
AU2015238298B2 (en) * 2014-03-27 2019-04-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
DK3174858T3 (da) 2014-07-31 2019-07-15 Basf Se Fremgangsmåde til fremstilling af pyrazoler
US9938100B2 (en) 2014-12-30 2018-04-10 Kodak Alaris Inc. System and method for metallic object detection in a media transport system
JP6833718B2 (ja) 2015-05-11 2021-02-24 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ ４−アミノ−ピリダジンを製造するための方法
AU2015401326B2 (en) * 2015-07-03 2018-07-26 China Agricultural University Benzylhydrazone compounds and preparation method and application thereof
PL3411360T3 (pl) * 2016-02-02 2020-08-24 Basf Se Sposób katalitycznego uwodorniania dla wytwarzania pirazoli
CN107174585A (zh) * 2016-03-10 2017-09-19 兰州大学 可用作雄激素受体拮抗剂的吡啶并咪唑类化合物的新用途
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) * 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018024644A1 (en) * 2016-08-02 2018-02-08 Solvay Sa Manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives, hydrazinyl compounds and their use
KR102411532B1 (ko) * 2016-09-09 2022-06-22 노파르티스 아게 엔도솜 톨-유사 수용체의 억제제로서의 화합물 및 조성물
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
US11111249B2 (en) 2017-05-18 2021-09-07 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl-pyrazole derivative, and preparation method therefor and medical application thereof
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
US11130756B2 (en) 2017-08-04 2021-09-28 Bristol-Myers Squibb Company [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds
JP7265554B2 (ja) 2017-11-14 2023-04-26 ブリストル－マイヤーズ スクイブ カンパニー 置換インドール化合物
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
ES2927960T3 (es) * 2017-12-15 2022-11-14 Bristol Myers Squibb Co Compuestos de indol éter sustituidos
CN111819176B (zh) 2017-12-18 2023-12-15 百时美施贵宝公司 4-氮杂吲哚化合物
AU2018390543A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
MX2020005515A (es) 2017-12-19 2020-09-03 Bristol Myers Squibb Co Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
WO2019126113A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
CA3086431A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
CA3085942A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
AU2018390544A1 (en) * 2017-12-20 2020-08-06 Bristol-Myers Squibb Company Diazaindole compounds
US20210171468A1 (en) * 2017-12-22 2021-06-10 Solvay Sa Process for the manufacture of pyrazole carboxylic derivatives and precursors thereof
WO2019123294A2 (en) 2017-12-22 2019-06-27 Novartis Ag Novel uses of pyrazolo piperidine derivatives
EP3805203A4 (en) * 2018-06-07 2022-02-23 Daiichi Sankyo Company, Limited AZETIDE DERIVATIVE AND PRODRUG THEREOF
US20210355122A1 (en) * 2018-09-06 2021-11-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
CN113039185A (zh) * 2018-11-09 2021-06-25 豪夫迈·罗氏有限公司 5-[6-[[3-(4,5,6,7-四氢吡唑并[4,3-c]吡啶-1-基)氮杂环丁烷-1-基]甲基]吗啉-4-基]喹啉-8-腈衍生物和类似化合物作为tlr7-9拮抗剂用于治疗系统性红斑狼疮
KR20210125025A (ko) * 2019-02-07 2021-10-15 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
CN114206872A (zh) * 2019-08-02 2022-03-18 百济神州有限公司 咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物作为tlr8激动剂
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
US20230097700A1 (en) * 2019-12-06 2023-03-30 Daiichi Sankyo Company, Limited Azetidine sulfonamide compound
EP4323369A1 (en) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Thienopyrrole compounds

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3116230B2 (ja) 1989-02-15 2000-12-11 武田薬品工業株式会社 三環式縮合ピリミジン誘導体
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
FR2733749B1 (fr) 1995-05-05 1997-06-13 Oreal Compositions pour la teinture des fibres keratiniques contenant des diamino pyrazoles, procede de teinture, nouveaux diamino pyrazoles et leur procede de preparation
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US6472416B1 (en) 1999-08-27 2002-10-29 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
CZ20031554A3 (cs) 2000-12-06 2003-08-13 Aventis Pharma Deutschland Gmbh Guanidinové a amidinové deriváty jako inhibitory faktoru XA
IL157895A0 (en) * 2001-03-14 2004-03-28 Gruenenthal Chemie Substituted pyrazolopyrimidines and thiazolopyrimidines
AU2003219410A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
DE10221100C1 (de) 2002-05-03 2003-06-05 Neuhaus Elektronik Gmbh Elektrisch leitfähige Dichtung sowie Verfahren und Vorrichtung zu deren Herstellung
JP2003327860A (ja) 2002-05-09 2003-11-19 Konica Minolta Holdings Inc 着色組成物、着色微粒子分散物、インクジェット用インク、インクジェット記録方法
US6800625B2 (en) 2002-06-19 2004-10-05 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo[3,4-b]quinolin-9-one derivatives useful as phosphodiesterase inhibitors
JP4133055B2 (ja) 2002-07-11 2008-08-13 株式会社イトーキ 移載機構を備えた自動倉庫
ES2635838T3 (es) 2002-08-26 2017-10-05 Takeda Pharmaceutical Company Limited Compuesto modulador de receptores de calcio y su uso
ZA200500782B (en) * 2002-08-26 2007-10-31 Takeda Pharmaceutical Calcium receptor modulating compound and use thereof
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004089415A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
AU2004236239A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
CA2527582A1 (en) 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
US20060025337A1 (en) 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
FR2865208B1 (fr) 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7279232B2 (en) 2004-01-26 2007-10-09 Universal Display Corporation Electroluminescent stability
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
US7825265B2 (en) 2004-05-04 2010-11-02 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
WO2005108337A2 (en) 2004-05-04 2005-11-17 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptor
EP1812426B1 (en) 2004-10-12 2011-06-08 Decode Genetics, Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
EP1844043A2 (en) 2004-11-18 2007-10-17 The Institutes for Pharmaceutical Discovery, LLC Heterocycle substituted carboxylic acids for the treatment of diabetes
EP1829863A4 (en) 2004-11-26 2009-04-22 Takeda Pharmaceutical ARYLALCANOIC ACID DERIVATIVE
EP1841415A2 (en) 2005-01-20 2007-10-10 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
EP1900728A1 (en) 2005-05-30 2008-03-19 Genecare Research Institute Co., Ltd Pharmaceutical composition comprising pyrazolone derivative
EP1905762A1 (en) 2005-05-30 2008-04-02 Genecare Research Institute Co., Ltd Pyrazolone derivative
EP1888512A2 (en) 2005-06-06 2008-02-20 Smithkline Beecham Corporation Chemical compounds
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
KR20080049758A (ko) 2005-09-01 2008-06-04 아스텔라스세이야쿠 가부시키가이샤 통증 치료용으로 사용되는 피리다지논 유도체
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
JPWO2007102531A1 (ja) 2006-03-08 2009-07-23 武田薬品工業株式会社 併用薬
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
US7851495B2 (en) 2006-05-23 2010-12-14 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2439206A1 (en) 2006-05-23 2012-04-11 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CN101490001A (zh) 2006-06-09 2009-07-22 Icos股份有限公司 用作dp-2拮抗剂的取代的苯乙酸
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Ａｌｋ−５阻害剤としてのピリミジン誘導体
WO2008015270A1 (en) * 2006-08-04 2008-02-07 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2008033894A2 (en) 2006-09-14 2008-03-20 Acadia Pharmaceuticals Inc. Compounds with activity at estrogen receptors
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
EP2117311A4 (en) 2007-02-08 2011-05-11 Merck Sharp & Dohme THERAPEUTICS
EP2009002A1 (en) 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CN101889014A (zh) * 2007-11-15 2010-11-17 卫材R&D管理有限公司 富含对映体的咪唑并吖庚因酮化合物
KR20100102646A (ko) * 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
US20120010177A1 (en) 2008-02-20 2012-01-12 The Wistar Institute / North Carolina State University MicroRNA Modulators and Method for Identifying And Using The Same
WO2010051048A1 (en) 2008-02-20 2010-05-06 The Wistar Institute Microrna modulators and method for identifying and using the same
US20110003849A1 (en) 2008-03-04 2011-01-06 Hong Shen Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
WO2009148961A2 (en) 2008-05-29 2009-12-10 Wisconsin Alumni Research Foundation Drugs to prevent hpv infection
CA2727242A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of faah
CA2727245A1 (en) 2008-06-11 2009-12-17 Merck Sharp & Dohme Corp. Imidazole derivatives useful as inhibitors of faah
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
JP2011524894A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
WO2009158396A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketopiperidine derivatives as hiv attachment inhibitors
WO2009158394A1 (en) 2008-06-25 2009-12-30 Bristol-Myers Squibb Company Diketo azolopiperidines and azolopiperazines as anti-hiv agents
US8263642B2 (en) 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
AU2009276699A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
AU2009279874B2 (en) 2008-08-04 2015-02-12 Merck Sharp & Dohme Corp. Oxazole derivatives useful as inhibitors of FAAH
US20110251172A1 (en) 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
ES2797955T3 (es) 2008-08-25 2020-12-04 Novartis Ag Moduladores de la ruta de hedgehog
EP2346335B1 (en) 2008-09-24 2018-11-14 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010096115A1 (en) * 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US20100120778A1 (en) 2008-11-07 2010-05-13 Wyeth Quinoxaline-based lxr modulators
RU2011134637A (ru) 2009-01-19 2013-02-27 Дайити Санкио Компани, Лимитед Циклическое соединение, содержащее гетероатом
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
HUE047643T2 (hu) 2009-03-02 2020-05-28 Stemsynergy Therapeutics Inc Módszerek és készítmények rák kezelésére és a WNT által közvetített hatások csökkentésére egy sejtben
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20120141483A1 (en) 2009-06-04 2012-06-07 Mary Katherine Delmedico Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives
US20110021531A1 (en) 2009-07-27 2011-01-27 Chobanian Harry Oxazole derivatives useful as inhibitors of faah
EP2470183B1 (en) 2009-08-26 2015-09-16 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
UY33001A (es) 2009-11-06 2011-05-31 Boehringer Ingelheim Int Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011072064A1 (en) 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
FR2953837B1 (fr) 2009-12-10 2012-03-09 Sanofi Aventis Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique
WO2011079000A1 (en) 2009-12-22 2011-06-30 Schering Corporation DERIVATIVES OF 7,8-DIHYDRO-1H-IMIDAZO[2,1-b]PURIN-4(5H)-ONE AND METHODS OF USE THEREOF
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
CN102858338A (zh) 2010-01-28 2013-01-02 默沙东公司 治疗疼痛及其它适应症的药物组合物
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
EP2371219A1 (en) 2010-04-01 2011-10-05 Basf Se Herbicidal acylhydrazides
EP2555768B1 (en) 2010-04-05 2018-08-29 Fosun Orinove Pharmatech, Inc. Ire-1 inhibitors
CN103153307A (zh) 2010-04-22 2013-06-12 默沙东公司 用作faah调节剂的噁唑衍生物
US9301952B2 (en) 2010-04-23 2016-04-05 Kineta, Inc. Diarylpyridine anti-viral compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
CN102048738A (zh) 2010-12-08 2011-05-11 辽宁利锋科技开发有限公司 含有环嘧耐平药用复合物的药物组合物制剂
CN110372673B (zh) 2011-07-29 2023-10-03 卡尔约药物治疗公司 含酰肼的核运输调节剂及其用途
EA201490406A1 (ru) 2011-07-29 2014-07-30 Кариофарм Терапевтикс, Инк. Модуляторы ядерного транспорта и их применение
JP2013159564A (ja) * 2012-02-02 2013-08-19 Kowa Co ピラゾロピリミジン−７−アミン誘導体を有効成分とするｔｌｒ９阻害剤
TW201336851A (zh) 2012-02-13 2013-09-16 必治妥美雅史谷比公司 烯二炔化合物，其共軛物及彼等之用途與方法
KR101742954B1 (ko) 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين

Also Published As

Publication number Publication date
WO2013181579A3 (en) 2014-03-27
IL235986A0 (en) 2015-02-01
RS57977B1 (sr) 2019-01-31
IL268013B1 (en) 2024-01-01
HUE040562T2 (hu) 2019-03-28
US20200347050A1 (en) 2020-11-05
IL235986B (en) 2019-11-28
KR20150016366A (ko) 2015-02-11
RU2014154397A (ru) 2016-07-27
IL268013A (en) 2019-09-26
AU2017204586B2 (en) 2018-11-08
ES2709119T3 (es) 2019-04-15
AU2017204586A1 (en) 2017-07-27
CN104507939A (zh) 2015-04-08
AU2013267204A8 (en) 2017-04-13
JP6619829B2 (ja) 2019-12-11
HK1203498A1 (en) 2015-10-30
HRP20181889T1 (hr) 2019-01-11
RU2677291C2 (ru) 2019-01-16
RU2733959C2 (ru) 2020-10-08
DK2855476T3 (en) 2018-12-17
US20160030430A1 (en) 2016-02-04
PH12014502660B1 (en) 2015-01-21
NZ703459A (en) 2016-09-30
PH12019500522A1 (en) 2020-11-04
US9850242B2 (en) 2017-12-26
US20130324547A1 (en) 2013-12-05
CA2874445A1 (en) 2013-12-05
RU2018146532A (ru) 2019-01-31
PE20150220A1 (es) 2015-02-14
WO2013181579A2 (en) 2013-12-05
AR091236A1 (es) 2015-01-21
EP2855476A2 (en) 2015-04-08
BR112014030060B1 (pt) 2022-05-31
BR112014030060A2 (pt) 2017-09-12
EP2855476B1 (en) 2018-09-05
KR102403007B1 (ko) 2022-05-31
US20160339032A1 (en) 2016-11-24
SG11201407890VA (en) 2014-12-30
AU2013267204A1 (en) 2015-01-29
JP2018087221A (ja) 2018-06-07
CN104507939B (zh) 2017-07-25
TW201402575A (zh) 2014-01-16
PT2855476T (pt) 2018-12-03
IL268013B2 (en) 2024-05-01
AU2013267204B8 (en) 2017-04-13
CN107344941B (zh) 2020-04-21
JP6285918B2 (ja) 2018-02-28
LT2855476T (lt) 2019-01-10
ZA201409273B (en) 2016-05-25
SI2855476T1 (sl) 2018-12-31
US9446046B2 (en) 2016-09-20
KR20210076210A (ko) 2021-06-23
PE20190973A1 (es) 2019-07-09
CA2874445C (en) 2022-06-21
CN107344941A (zh) 2017-11-14
MX368455B (es) 2019-10-03
JO3407B1 (ar) 2019-10-20
KR102268155B1 (ko) 2021-06-24
US11130758B2 (en) 2021-09-28
US20180273532A1 (en) 2018-09-27
PH12014502660A1 (en) 2015-01-21
MX2014014497A (es) 2015-06-02
US9126999B2 (en) 2015-09-08
TWI572606B (zh) 2017-03-01
MY172926A (en) 2019-12-14
JP2015523981A (ja) 2015-08-20
CL2014003278A1 (es) 2015-06-12
PL2855476T3 (pl) 2019-02-28
RU2018146532A3 (el) 2019-06-21
UA113440C2 (xx) 2017-01-25
US10640500B2 (en) 2020-05-05
AU2013267204B2 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CY1122692T1 (el) Ενωσεις τετραϋδροπυραζολοπυριμιδινης
CY1122776T1 (el) Επιλεκτικως υποκατεστημενες ενωσεις κινολινης
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
MX2016004629A (es) Compuestos de quinolina selectivamente sustituidos.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201591960A1 (ru) Ингибиторы акк и их применение
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201592157A1 (ru) Низкомолекулярные ингибиторы фиброза
EA201591962A1 (ru) Ингибиторы акк и их применение
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
ES2523418R2 (es) Procedimiento de obtencion de composiciones protegidas para alimentacion animal, composiciones y uso de las mismas
EA201600032A1 (ru) Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
ITUA20164278A1 (it) COMPOSTI 2-OXO-1,2-DIIDROPIRIDIN-3-CARBOSSAMMIDE E LORO USO COME INIBITORI DUALI DI PDK1/AurA
TH168487B (th) สารประกอบควิโนลีนที่ถูกแทนที่อย่างเลือกได้ (Selectively Substituted Quinoline Compounds)